03-13-2018 04:35 PM CET - Industry, Real Estate & Construction
Print

Sexually Transmitted Diseases (STDs) Drug Market Likely to Touch CAGR at a 11.2% by 2025

Press release from: Market Research Reports Search Engine - MRRSE
Market Research Reports Search Engine (MRRSE)
Market Research Reports Search Engine (MRRSE)
A latest research report titled as “Sexually Transmitted Diseases (STDs) Drug Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or investors. It includes an exhaustive enquiry with the reliability of logic and the comprehensiveness of contents.

Click here For Free Sample Report @ www.mrrse.com/sample/3950

Sexually transmitted diseases (STDs), also referred as venereal diseases are infections that can pass from person to person during sex. These diseases are caused mainly due to bacteria, viruses, and / or parasites. Sexually transmitted diseases (STDs) often go undiagnosed because these infections usually do not exhibit visual symptoms. Changes in urination, Pain during sex, unusual discharge from the penis, abnormal vaginal discharge or bleeding, bumps or sores, pain in the pelvic or abdominal region, burning or itching in the vaginal area are most common symptoms for sexually transmitted diseases (STDs). These all symptoms help to diagnose sexually transmitted diseases (STDs). Nucleic Acid Amplification Tests (NAAT), direct fluorescent tests and others test recommended by healthcare specialist to confirm sexually transmitted diseases (STDs). Chlamydia, gonorrhea, HIV/AIDS, Human papillomavirus infection and syphilis are the most common types of sexually transmitted diseases (STDs. As per WHO 2015 report, near about 1.1 billion people had sexually transmitted diseases (STDs) other than HIV/AIDS. About 500 million people were infected with either chlamydia, gonorrhea syphilis or trichomoniasis. At least 250 million women suffering from human papillomavirus while 530 million case find with genital herpes.

Hospital Segment to Turn Lucrative, Fuelling Demand for Sexually Transmitted Disease Drugs

The global market for sexually transmitted diseases (STDs) drug is expanding significantly, owing to increased chances of infection led by increase in the life expectancy of people across the globe. Rise in incidences of unprotected sex has led to an increase in the prevalence of sexually transmitted diseases. A driving factor for the sexually transmitted diseases (STDs) drug is rising initiatives by governments and multiple agencies drawn up guidelines or recommendations for sexually transmitted diseases (STDs). Low voluntary screening rate for sexually transmitted diseases (STDs) is major restrain for this market.

Browse Full Report with TOC @ www.mrrse.com/sexually-transmitted-disease-drugs-market

The global sexually transmitted diseases (STDs) drug market can be segmented on the basis of disease type, therapy class, distribution channel, and region. On the bases of disease type, sexually transmitted diseases (STDs) drug market can be further segmented into chlamydia, gonorrhea, syphilis, human papillomavirus infection, HIV/AIDS and others. According to therapy class sexually transmitted diseases (STDs) drug market can be segmented into antibiotics, antiviral, vaccines and others. In terms of distribution channel, the sexually transmitted diseases (STDs) drug market can be segmented into hospitals pharmacies, retail pharmacies, online pharmacies and others. In terms of revenue, the hospitals segment held a significant share of the sexually transmitted diseases (STDs) drug market in 2016.

Rising Demand from Developing Economies to Support Market’s Expansion in Asia Pacific

In terms of region, the global sexually transmitted diseases (STDs) drug market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for sexually transmitted diseases (STDs) drug market, followed by Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, the U.S. holds a major share of the sexually transmitted diseases (STDs) drug market in North America. The market in Europe is expanding rapidly, due to increase in the patient population, especially in UK, Germany. Moreover, the market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and Japan are projected to contribute to growth of the market in APAC between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increasing education awareness.

Key players operating in the global sexually transmitted diseases drug market are Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb Co. AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, and Merck & Co., Inc.

Enquire about this Report @ www.mrrse.com/enquiry/3950

About Market Research Reports Search Engine

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: www.mrrse.com/
Read More Industry News At: www.industrynewsanalysis.com/

This release was published on openPR.
News-ID: 977100 • Views: 325
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: